Related Party Transactions (Details Narrative) |
9 Months Ended | 12 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May 14, 2019
USD ($)
$ / shares
shares
|
May 14, 2019
AUD ($)
shares
|
Mar. 14, 2019
USD ($)
|
Mar. 14, 2019
AUD ($)
|
Mar. 16, 2018
USD ($)
|
Mar. 16, 2018
AUD ($)
|
Feb. 01, 2018
USD ($)
|
Feb. 01, 2018
AUD ($)
|
May 05, 2016
USD ($)
|
May 05, 2016
AUD ($)
|
Apr. 14, 2016
$ / shares
|
Feb. 25, 2016
USD ($)
|
Feb. 25, 2016
AUD ($)
|
Feb. 25, 2015
AUD ($)
|
Mar. 31, 2019
AUD ($)
|
Jun. 30, 2019
USD ($)
$ / shares
|
Jun. 30, 2019
AUD ($)
|
Jun. 30, 2018
USD ($)
$ / shares
|
Jun. 30, 2018
AUD ($)
|
Jun. 30, 2019
AUD ($)
|
May 05, 2016
AUD ($)
|
|
| Loans from related party | $ 51,867 | $ 54,753 | |||||||||||||||||||
| Due to related parties | $ 31,164 | $ 32,898 | |||||||||||||||||||
| Excercise price | $ / shares | |||||||||||||||||||||
| Stock price | $ / shares | $ 6.00 | ||||||||||||||||||||
| Chief Executive Officer [Member] | |||||||||||||||||||||
| Payments form related party | $ 64,377 | ||||||||||||||||||||
| Bonus payable amount | 143,060 | ||||||||||||||||||||
| Remaining bonus amount | 185,978 | ||||||||||||||||||||
| Granted exercise price | $ / shares | $ 3,750 | ||||||||||||||||||||
| Nathanielsz Employment Agreement [Member] | |||||||||||||||||||||
| Expired date | Feb. 25, 2018 | ||||||||||||||||||||
| Annual salary | $ 214,590 | ||||||||||||||||||||
| Percentage of pension of monthly salary | 9.50% | 9.50% | |||||||||||||||||||
| Percentage of bonus of annual base salary | 200.00% | 200.00% | |||||||||||||||||||
| Nathanielsz Employment Agreement [Member] | Minimum [Member] | |||||||||||||||||||||
| Annual salary | $ 211,380 | ||||||||||||||||||||
| Nathanielsz Employment Agreement [Member] | Maximum [Member] | |||||||||||||||||||||
| Annual salary | $ 286,120 | ||||||||||||||||||||
| AUD Currency [Member] | Board of Directors [Member] | |||||||||||||||||||||
| Payments form related party | $ 80,046 | ||||||||||||||||||||
| AUD Currency [Member] | Chief Executive Officer [Member] | |||||||||||||||||||||
| Payments form related party | $ 90,000 | ||||||||||||||||||||
| Bonus payable amount | 200,000 | ||||||||||||||||||||
| Remaining bonus amount | 260,000 | ||||||||||||||||||||
| AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | |||||||||||||||||||||
| Annual salary | $ 25,000 | 300,000 | |||||||||||||||||||
| AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Minimum [Member] | |||||||||||||||||||||
| Annual salary | $ 300,000 | ||||||||||||||||||||
| AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Maximum [Member] | |||||||||||||||||||||
| Annual salary | 400,000 | ||||||||||||||||||||
| Initial Nathanielsz RSUs [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Restricted stock shares of common stock | shares | 39,000 | 39,000 | |||||||||||||||||||
| Additional Nathanielsz RSUs [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Restricted stock shares of common stock | shares | 39,000 | 39,000 | |||||||||||||||||||
| RSUS vest, shares | shares | 7,800 | 7,800 | |||||||||||||||||||
| Gross proceeds from equity financing | $ 4,000,000 | ||||||||||||||||||||
| Restricted Stock Units [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Restricted stock shares of common stock | shares | 78,000 | 78,000 | |||||||||||||||||||
| Stock price | $ / shares | $ 4.25 | ||||||||||||||||||||
| Restricted stock value | $ 331,500 | ||||||||||||||||||||
| Fair value of restricted stock | $ 165,747 | ||||||||||||||||||||
| Initial Kenyon RSUs [Member] | Services Agreement [Member] | |||||||||||||||||||||
| Restricted stock shares of common stock | shares | 19,500 | 19,500 | |||||||||||||||||||
| Additional Kenyon RSUs [Member] | Services Agreement [Member] | |||||||||||||||||||||
| Restricted stock shares of common stock | shares | 19,500 | 19,500 | |||||||||||||||||||
| RSUS vest, shares | shares | 4,875 | 4,875 | |||||||||||||||||||
| Gross proceeds from equity financing | $ 4,000,000 | ||||||||||||||||||||
| North Horizon Pty Ltd [Member] | |||||||||||||||||||||
| Lease term | 5 years | 5 years | |||||||||||||||||||
| Annual rental payments | $ 28,325 | ||||||||||||||||||||
| Goods and service tax | 2,575 | ||||||||||||||||||||
| Future minimum payments due | $ 54,291 | ||||||||||||||||||||
| North Horizon Pty Ltd [Member] | AUD Currency [Member] | |||||||||||||||||||||
| Annual rental payments | $ 39,600 | ||||||||||||||||||||
| Goods and service tax | $ 3,600 | ||||||||||||||||||||
| Future minimum payments due | $ 75,900 | ||||||||||||||||||||
| Current and Former Director [Member] | |||||||||||||||||||||
| Loans from related party | 51,867 | $ 54,753 | |||||||||||||||||||
| Former Director [Member] | |||||||||||||||||||||
| Due to related parties | 31,164 | $ 32,898 | |||||||||||||||||||
| Nathanielsz [Member] | North Horizon Pty Ltd [Member] | |||||||||||||||||||||
| Future minimum payments due | $ 141,629 | ||||||||||||||||||||
| Nathanielsz [Member] | North Horizon Pty Ltd [Member] | AUD Currency [Member] | |||||||||||||||||||||
| Future minimum payments due | $ 198,000 | ||||||||||||||||||||
| Mr. Nathanielsz [Member] | |||||||||||||||||||||
| Annual salary | $ 53,648 | ||||||||||||||||||||
| Payments form related party | 38,463 | ||||||||||||||||||||
| Mr. Nathanielsz [Member] | AUD Currency [Member] | |||||||||||||||||||||
| Annual salary | $ 75,000 | ||||||||||||||||||||
| Payments form related party | 53,772 | ||||||||||||||||||||
| Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member] | |||||||||||||||||||||
| Payments form related party | $ 219,954 | ||||||||||||||||||||
| James Nathanielsz [Member] | |||||||||||||||||||||
| Payments form related party | $ 3,205 | ||||||||||||||||||||
| James Nathanielsz [Member] | AUD Currency [Member] | |||||||||||||||||||||
| Payments form related party | $ 4,481 | ||||||||||||||||||||
| Mr. Nathanielsz [Member] | |||||||||||||||||||||
| Paid in relation to bouns amount | $ 157,333 | ||||||||||||||||||||
| Mr. Nathanielsz [Member] | Board of Directors [Member] | |||||||||||||||||||||
| Officers' compensation | $ 329,038 | ||||||||||||||||||||
| Mr. Nathanielsz [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Agreement term | 3 years | 3 years | |||||||||||||||||||
| Agreement renewal term | 1 year | 1 year | |||||||||||||||||||
| Option purchase shares | shares | 39,000 | 39,000 | |||||||||||||||||||
| Excercise price | $ / shares | $ 4.675 | ||||||||||||||||||||
| Market price | 110.00% | 110.00% | |||||||||||||||||||
| Granted exercise price | $ / shares | $ 4.25 | ||||||||||||||||||||
| Restricted stock shares of common stock | shares | 39,000 | 39,000 | |||||||||||||||||||
| Option term | 10 years | 10 years | |||||||||||||||||||
| Options vested, description | The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event. | The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event. | |||||||||||||||||||
| Stock price | $ / shares | $ 4.25 | ||||||||||||||||||||
| Restricted stock value | $ 165,747 | ||||||||||||||||||||
| Exercise price | $ / shares | $ 4.65 | ||||||||||||||||||||
| Dividend yield | 0.00% | 0.00% | |||||||||||||||||||
| Years to maturity | 10 years | 10 years | |||||||||||||||||||
| Risk free rate | 2.42% | 2.42% | |||||||||||||||||||
| Expected volatility | 268.00% | 268.00% | |||||||||||||||||||
| Mr. Nathanielsz [Member] | AUD Currency [Member] | |||||||||||||||||||||
| Paid in relation to bouns amount | $ 219,954 | ||||||||||||||||||||
| Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member] | |||||||||||||||||||||
| Officers' compensation | $ 460,000 | $ 300,000 | |||||||||||||||||||
| Mr. Nathanielsz [Member] | AUD Currency [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Annual salary | $ 400,000 | ||||||||||||||||||||
| Dr Kenyon [Member] | AUD Currency [Member] | Services Agreement [Member] | |||||||||||||||||||||
| Annual salary | $ 54,000 | ||||||||||||||||||||
| Dr Kenyon [Member] | Services Agreement [Member] | |||||||||||||||||||||
| Agreement term | 3 years | 3 years | |||||||||||||||||||
| Agreement renewal term | 1 year | 1 year | |||||||||||||||||||
| Option purchase shares | shares | 19,500 | 19,500 | |||||||||||||||||||
| Excercise price | $ / shares | $ 4.25 | ||||||||||||||||||||
| Market price | 100.00% | 100.00% | |||||||||||||||||||
| Granted exercise price | $ / shares | $ 19,500 | ||||||||||||||||||||
| Option term | 10 years | 10 years | |||||||||||||||||||
| Options vested, description | The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event. | The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event. | |||||||||||||||||||
| Stock price | $ / shares | $ 4.25 | ||||||||||||||||||||
| Restricted stock value | $ 82,873 | ||||||||||||||||||||
| Exercise price | $ / shares | $ 4.25 | ||||||||||||||||||||
| Dividend yield | 0.00% | 0.00% | |||||||||||||||||||
| Years to maturity | 10 years | 10 years | |||||||||||||||||||
| Risk free rate | 2.42% | 2.42% | |||||||||||||||||||
| Expected volatility | 268.00% | 268.00% | |||||||||||||||||||
| Dr Kenyon [Member] | Restricted Stock [Member] | Services Agreement [Member] | |||||||||||||||||||||
| Restricted stock shares of common stock | shares | 39,000 | 39,000 | |||||||||||||||||||
| Stock price | $ / shares | $ 4.25 | ||||||||||||||||||||
| Restricted stock value | $ 165,750 | ||||||||||||||||||||
| Fair value of restricted stock | $ 82,873 | ||||||||||||||||||||